

# Jing Sun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4619853/publications.pdf>

Version: 2024-02-01

17  
papers

312  
citations

1162367

8  
h-index

996533

15  
g-index

17  
all docs

17  
docs citations

17  
times ranked

347  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing waiting time and raising outpatient satisfaction in a Chinese public tertiary general hospital-an interrupted time series study. <i>BMC Public Health</i> , 2017, 17, 668.	1.2	78
2	Consumer satisfaction with tertiary healthcare in China: findings from the 2015 China National Patient Survey. <i>International Journal for Quality in Health Care</i> , 2017, 29, 213-221.	0.9	48
3	How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. <i>Journal of Global Health</i> , 2019, 9, 020702.	1.2	35
4	Impact of adverse media reporting on public perceptions of the doctor-patient relationship in China: an analysis with propensity score matching method. <i>BMJ Open</i> , 2018, 8, e022455.	0.8	32
5	A review of promoting access to medicines in China - problems and recommendations. <i>BMC Health Services Research</i> , 2018, 18, 125.	0.9	21
6	How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. <i>Journal of Global Health</i> , 2019, 9, 020702.	1.2	15
7	What China can learn from Malaysia to achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 16, 100261.	1.3	15
8	How government health insurance coverage of novel anti-cancer medicines benefited patients in China - a retrospective analysis of hospital clinical data. <i>BMC Health Services Research</i> , 2021, 21, 856.	0.9	13
9	Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012-2020. <i>BMJ Global Health</i> , 2021, 6, e007089.	2.0	12
10	International experiences of promoting generics use and its implications to China. <i>Journal of Evidence-Based Medicine</i> , 2013, 6, 74-80.	2.4	9
11	How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?. <i>Journal of Medical Economics</i> , 2016, 19, 881-888.	1.0	8
12	The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China-In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 778940.	1.6	7
13	Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective. <i>Risk Management and Healthcare Policy</i> , 2019, Volume 12, 357-367.	1.2	6
14	Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin. <i>Annals of Global Health</i> , 2020, 86, 36.	0.8	6
15	Impact of public health insurance coverage of novel anticancer medication on medical expenditure and patient affordability in a provincial medical centre of China: a propensity score-matching analysis with the quasi-experimental design. <i>BMJ Open</i> , 2022, 12, e054713.	0.8	4
16	Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013-2020). <i>Liver International</i> , 2022, 42, 1762-1769.	1.9	2
17	Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China. <i>Infectious Diseases and Therapy</i> , 0, , .	1.8	1